Global Health Industry Headlines: IPOs, Drug Breakthroughs, and Policy Shifts
Recent health news highlights include Grifols' U.S. biopharma business planning an IPO, Kodiak Sciences’ share surge after a successful study, and a bipartisan U.S. Senate deal to cap insulin prices at $35. Several companies face FDA challenges, fresh drug approvals are noted, and global policies impacting health are addressed.
Spanish drugmaker Grifols has decided to launch an initial public offering for its U.S. biopharma business, planning to float a minority stake while maintaining majority ownership.
Kodiak Sciences witnessed a significant boost in its share value after successfully trialing an eye drug targeting diabetic retinopathy.
In a notable legislative move, U.S. senators reached a bipartisan agreement to cap insulin prices at $35, seeking swift action before Senator Shaheen's retirement.
ALSO READ
-
SEBI Insists on Ensuring Fair Play in Par Drugs and Chemicals Business Sale
-
Mirabai Chanu's Unfinished Business: The Quest for an Asian Games Medal
-
Putin Set to Engage with Russian Business Leaders
-
NZ Moves 60+ Business Surveys Online in Major Push to Cut Red Tape for SMEs
-
Biopharmaceutical Innovations and Global Drug Market Dynamics
Google News